Needham & Company LLC reiterated their buy rating on shares of Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) in a research note published on Tuesday, Benzinga reports. They currently have a $17.00 price objective on the stock. Other analysts have also issued research reports about the company. KeyCorp boosted their price target on Recursion Pharmaceuticals from […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) COO Tina Marriott Larson sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $8.66, for a total value of $25,980.00. Following the sale, the chief operating officer now directly owns 418,782 […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) COO Tina Marriott Larson sold 3,000 shares of the stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $8.66, for a total transaction of $25,980.00. Following the completion of the sale, the chief operating officer now directly owns 418,782 […]
Platinum Investment Management Ltd. grew its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 2.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,770,451 shares of the company’s stock after buying an additional 60,112 shares during the period. Platinum Investment Management Ltd.’s […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) shares saw unusually-strong trading volume on Thursday . Approximately 1,231,280 shares traded hands during trading, a decline of 61% from the previous session’s volume of 3,169,160 shares.The stock last traded at $8.81 and had previously closed at $9.38. Analysts Set New Price Targets A number of analysts […]